Skip to main content

Table 1 The clinical application of systematic chemotherapy plus surgery for gastric cancer patients with peritoneal metastasis

From: Issues on peritoneal metastasis of gastric cancer: an update

Authors
reference
Year Country Patients N of PM Systemic
therapy
MST
(m)
1-year
OS (%)
R0 resection (%)
Ishigami et al. [30] 2008 Japan Stage IV GC 9 PTX+S1 -- -- 88.9
Okabe et al. [31] 2009 Japan GC patients with PM 41 S-1 plus DDP 43.2 100 57.9%
Einama et al. [32] 2017 Japan Stage IV GC 3 S1 + DDP/DTX 14.3 100 100
Kanda et al. [33] 2012 USA GC with PM 19 5-Fu+
oxaliplatin
30.2 94.7 26.3
Han et al. [34] 2013 Korea M1 GC 8 FOLFOX/DCF - - 50
Fukuchi et al. [35] 2018 Japan Unresectable GC 44 SP et al - - 38.6
Satoh et al. [36] 2012 Japan Stage IV GC 17 S-1 plus DDP 43.5 - 82.4
Sato et al. [37] 2017 Japan Unresectable metastatic GC 33 DCS 28 97 27.3
Yamaguchi et al. [38] 2018 Japan Stage IV GC 115 SP et al - - -
Beom et al. [39] 2018 Korea Stage IV GC 33 Platinum+5-FU - - -
Ramos et al. [40] 2019 Brazil Unresectable GC 1 XP et al - - -
Kim [41] 2014 Korea GC patients with PM 43 5-Fu/titanium silicate-1+DDP 37 - 23.3
  1. DDP, cisplatin; DTX, docetaxel; HIPEC, hyperthermic intraperitoneal chemoperfusion; MMC, mitomycin C; PTX, paclitaxel; FOLFOX, 5-FU, oxaliplatin and leucovorin; DCF, docetaxel, cisplatin, and 5-FU; SP, S-1 plus paclitaxel; DCS, docetaxel, cisplatin, and S-1; XP, capecitabine and cisplatin